Preprint · OA
via OpenAlex
Characterization of human senescent cell biomarkers for clinical trials
Joshua N. Farr, David G. Monroe, Elizabeth J. Atkinson, Mitchell N. Froemming, Ming M. Ruan, Nathan K. LeBrasseur, Sundeep Khosla
medRxiv · 2024
Genomic instability
Cellular senescence
Senolytics
Telomerase activation
Cell culture / in vitro
Human
In vitro
Abstract
ABSTRACT There is an increasing need for blood-based biomarkers of senescent cell burden to facilitate selection of participants for clinical trials. Potential candidates include p16 Ink4a expression in peripheral blood T-cells and circulating protein concentrations of the senescence(definition)-associated secretory phenotype (SASP). p16 Ink4a is encoded by the CDKN2A locus, which produces six variant transcripts in humans, two of which encode homologous p16 proteins: p16 Inka4a , encoded by p16_variant 1 , and p16Ɣ, encoded by p16_variant 5 . While distinct quantitative polymerase chain reaction primers can be designed for p16_variant 5 , primers for p16_variant 1 also measure p16_variant 5 ( p16_variant 1+5 ). In a recent clinical trial evaluating effects of the senolytic combination, dasatinib + quercetin (D+Q), on bone metabolism in postmenopausal women, we found that women in the highest tertile for T-cell expression of p16_variant 5 had the most robust skeletal responses to D+Q. Importantly, assessment of p16_variant 5 was more predictive of these responses than p16_variant 1+5 . Here, we provide a comprehensive in vitro and in vivo characterization of p16_variant 5 expression. In vitro, p16_variant 1 increased rapidly (week 1) following the induction of DNA damage, whereas p16_variant 5 increased later (week 4), consistent with the latter being more specific for an established senescent state. Further analysis of our clinical trial data identified a SASP panel in plasma that correlated with p16_variant 5 expression in T-cells and performed as well in identifying postmenopausal women with a positive skeletal response to D+Q. Collectively, our findings support that the assessment of T-cell p16_variant 5 expression may be more specific for senescence and provide further support for this assay as a biomarker for selecting participants in clinical trials of senolytic interventions. In addition, our data indicate that correlated plasma SASP markers could be used in lieu of the more technically challenging T-cell p16 assay. Finally, the ability to identify individuals with a beneficial skeletal response to D+Q using two different measures of senescent cell burden (i.e., the T-cell p16 assay and the SASP score) provides further support for the hypothesis that the underlying senescent cell burden dictates the clinical response to a senolytic intervention.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1101/2024.11.02.24316643
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
Farr, J.N., Monroe, D.G., Atkinson, E.J., Froemming, M.N., Ruan, M.M., LeBrasseur, N.K., & Khosla, S. (2024). Characterization of human senescent cell biomarkers for clinical trials. <em>medRxiv</em>. https://doi.org/10.1101/2024.11.02.24316643
Vancouver
Farr JN, Monroe DG, Atkinson EJ, Froemming MN, Ruan MM, LeBrasseur NK, et al. Characterization of human senescent cell biomarkers for clinical trials. medRxiv. 2024. doi:10.1101/2024.11.02.24316643.
BibTeX
@unpublished{joshua2024Charac,
title = {Characterization of human senescent cell biomarkers for clinical trials},
author = {Joshua N. Farr and David G. Monroe and Elizabeth J. Atkinson and Mitchell N. Froemming and Ming M. Ruan and Nathan K. LeBrasseur and Sundeep Khosla},
journal = {medRxiv},
year = {2024},
doi = {10.1101/2024.11.02.24316643},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging Cell 2025
Open access · CC-BY
Characterization of Human Senescent Cell Biomarkers for Clinical Trials
bioRxiv (Cold Spring Harbor Laboratory) 2023
Preprint · CC-BY
Multiparametric senescent cell phenotyping reveals CD24 osteolineage cells as targets of senolytic therapy in the aged murine skeleton
EMBO Molecular Medicine 2026
Open access · CC-BY
Tomatidine is a senotherapeutic compound that improves cognitive function and reduces cellular senescence in aged mice
Nature Communications 2023
Open access · CC-BY
Multiparametric senescent cell phenotyping reveals targets of senolytic therapy in the aged murine skeleton
Cells 2023
Open access · CC-BY
Lipophilic Statins Eliminate Senescent Endothelial Cells by inducing Anoikis-Related Cell Death
PubMed 1996
Preprint · OA